Needham & Company LLC reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK - Free Report) in a report published on Wednesday,Benzinga reports. The firm currently has a $22.00 price target on the stock.
A number of other equities analysts have also recently commented on STOK. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. Leerink Partners began coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective on the stock. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating and a $24.00 price objective for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Stoke Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $21.29.
Check Out Our Latest Report on Stoke Therapeutics
Stoke Therapeutics Price Performance
NASDAQ:STOK traded down $0.35 during mid-day trading on Wednesday, reaching $8.96. 1,037,383 shares of the company's stock traded hands, compared to its average volume of 991,057. The company has a 50 day moving average price of $12.05 and a 200-day moving average price of $13.11. The firm has a market capitalization of $474.58 million, a price-to-earnings ratio of -4.27 and a beta of 0.95. Stoke Therapeutics has a 12-month low of $4.09 and a 12-month high of $17.58.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. As a group, analysts forecast that Stoke Therapeutics will post -2.03 EPS for the current year.
Insiders Place Their Bets
In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares of the company's stock, valued at $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Jonathan Allan sold 9,696 shares of the company's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the transaction, the general counsel now owns 35,142 shares in the company, valued at approximately $449,114.76. This represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock valued at $809,421 in the last three months. 11.30% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC acquired a new position in Stoke Therapeutics during the 2nd quarter worth about $29,000. Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics during the third quarter worth about $160,000. The Manufacturers Life Insurance Company boosted its stake in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock valued at $189,000 after purchasing an additional 1,994 shares during the period. Profund Advisors LLC acquired a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $201,000. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in Stoke Therapeutics during the 3rd quarter worth approximately $192,000.
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Further Reading
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
